Generation Bio Co.

NasdaqGS GBIO

Generation Bio Co. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2024: -104.85%

Generation Bio Co. Return on Equity (ROE) is -104.85% for the Trailing 12 Months (TTM) ending September 30, 2024, a -133.87% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Generation Bio Co. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -44.83%.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqGS: GBIO

Generation Bio Co.

CEO	Dr. Cameron Geoffrey McDonough M.D.
IPO Date	June 12, 2020
Location	United States
Headquarters	301 Binney Street
Employees	174
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years